SCHEMBL13077178

SCHEMBL13077178

C=C1C(=O)N(c2ccc(SC(F)(F)F)cc2)C(=O)N1CCC1CCCN1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.35
TDP1 Q9NUW8 3/20 0.35
DRD2 P14416 3/20 0.35
HTR2A P28223 3/20 0.35
HTR7 P34969 3/20 0.35
HTR6 P50406 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
TP53 P04637 2/20 0.35
CYP3A4 P08684 2/20 0.35
MAPK1 P28482 2/20 0.35
MAPT P10636 2/20 0.35
ADRA2A P08913 2/20 0.35
CHRM3 P20309 2/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
THPO P40225 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998141 0.78 IGF1R (0.54) IGF1R
SCHEMBL13177523 0.76 IGF1R (0.35) HTR2AMAPTHTR2CHTR2BHTT
SCHEMBL11448306 0.70 SLC2A1 (0.46) KCNH2
SCHEMBL13077014 0.70 IGF1R (0.40) TP53TSHRIGF1RKDM4E
SCHEMBL14215130 0.69 IGF1R (0.41) IGF1R
SCHEMBL11450110 0.69 SLC2A1 (0.44) KCNH2
SCHEMBL14224843 0.65 IGF1R (0.40) IGF1R
SCHEMBL13177440 0.65 IGF1R (0.49) IGF1R
SCHEMBL13076750 0.65 IGF1R (0.62) IGF1R
SCHEMBL14214986 0.64 LMNA (0.46) TDP1MAPK1MAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PIM1 456/4885TDP1 1345/4885DRD2 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.